Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02012296 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
A Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 4
- Study locations
NCT02012296 is a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer that has completed, run by University of Chicago. The registered enrollment target is 88 participants, below the 135-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (35% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02012296, a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 4
- Study locations
Study Summary
This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide and mifepristone, may lessen the amount of androgens made by the body. It is not yet known whether enzalutamide is more effective with or without mifepristone in treating patients with prostate cancer.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG enzalutamide
- OTHER pharmacological study
- DRUG mifepristone
Study Locations (4)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Cancer Care Specialists of Central Illinois (Decatur) /Decatur Memorial Hospital - Decatur
- NorthShore University Health System - Evanston
Michigan
- Wayne State University Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02012296
The ClinicalTrials.gov registry entry for NCT02012296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (35% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02012296 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT02012296 about?
NCT02012296 is a clinical study titled "Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer". This partially randomized phase I/II trial studies the side effects and best dose of enzalutamide and mifepristone when given together and to see how well they work in treating patients with metastatic hormone resistant prostate cancer. Androgens can cause the growth of prostate cancer cells. Antiho...
What is the current status of trial NCT02012296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2013-12-13. Estimated completion is 2020-08-01.
What conditions does trial NCT02012296 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT02012296?
The interventions under investigation include: laboratory biomarker analysis (OTHER), enzalutamide (DRUG), pharmacological study (OTHER), mifepristone (DRUG).
Who is sponsoring clinical trial NCT02012296?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02012296 being conducted?
This trial has 4 study locations across Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.